<DOC>
	<DOC>NCT02246673</DOC>
	<brief_summary>This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects and safety of RDEA3170 administered in combination with febuxostat compared to febuxostat administered alone in adult subjects with gout.</brief_summary>
	<brief_title>RDEA3170 and Febuxostat Combination Study in Gout Subjects</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first studyrelated activity. Meets one or more criteria for the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout. Body weight ≥ 50 kg (110 lbs) and a body mass index ≥ 18 and ≤ 45 kg/m2. Screening serum urate level ≥ 8 mg/dL. Free of any clinically significant disease or medical condition, per the Investigator's judgment. Unable to take colchicine for gout flare prophylaxis. History or suspicion of kidney stones. Any gastrointestinal disorder that affects motility and/or absorption. Unstable angina, New York Heart Association class III or IV heart failure, ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to Day 1; or subject is currently receiving anticoagulants. Screening laboratory parameters that are outside the normal limits and are considered clinically significant by the Investigator. Estimated creatinine clearance &lt; 60 mL/min calculated by the CockcroftGault formula using ideal body weight during the Screening period. Taking losartan, fenofibrate, guaifenesin, or sodiumglucose linked transporter2 inhibitors; chronic and stable doses are permitted if doses are stable for at least 14 days prior to study medication dosing. Unable or unwilling to comply with the study requirements or has a situation or condition that, in the opinion of the Investigator, may interfere with participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>